Aethlon Medical appoints James Frakes as permanent CEO of Investing.com

SAN DIEGO, CA – Aethlon Medical Inc. (NASDAQ:AEMD), a medical technology company, has been tapped by James B. Frakes to become permanent Chief Executive Officer. Frakes, on November 7, 2023, when interim CEO went to war, was later appointed Chief Financial Officer and the representative of the Verwaltungsraad.

Frakes has been with Aethlon Medical since January 2008 as Senior Vice President Finance, before taking on the position of Chief Financial Officer in September 2010. You can follow the background of the CFO positions at Left Behind Games Inc. and NTN Buzztime, Inc. There is an MBA degree from the University of Southern California and a Bachelor of Arts from Stanford University.

Im Zuge blessing Ernennung plant Aethlon Medical, de Konditionen von Frakes’ Anstellungsvertrag zu überarbeiten. The concrete of the underground, the small connections between Frakes and others Directors or leaders Angestellten des Unternehmens bestehen and keine meldepvlichtingen Transaktionen mit nahestehenden Personen vorliegen.

Zeitgleich with the CEO inheritance, Aethlon Medical ousted Guy F. Cipriani as Chief Operating Officer, probably with the Wirkung to the highest Tag. It is clear that the Ciprianis move is not being carried out in the way the economy is developing, or in the practice of internal economies. Gemäß de Beingungen seines Anstellungsvertrags vom 2. January 2021 wird Cipriani eine Abfindung erhalten, de zölf Monatsgehälter and dammit verbundene Leistungen umfasst, vorbehaltlich der Unterzeichnung aer Verzichts- und Freistellungsvereinbarung.

In continuing Aethlon Medical, Inc.’s active Entwicklungen reporting. for the first quarter of 2025 a net excess of US$2.6 million, there are solid bar money components of US$9.1 million. The third part has delivered a $3 million equity incentive plan – one of the actions generates more money for profit and talent retention.

Fortschritte verzeichnete Aethlon Medical with seinem Hemopurifier-Gerät. The study is based on the Medanta Institutional Ethics Committee’s full ethical issue for a clinical trial in India. Darüber began recruiting patients for a clinical trial of hemopurifiers in patients with solid tumors at the Royal Adelaide Hospital.

Many people like to do a preclinical study into the potential of the hemopurifier, the experience of kidney transplants with a kidney transplant, indemnity is harmful to the conservation of fluids involved.

In another company, Aethlon Medical has provided Generic care, the Anzahl of its automatic authorization action is an amount of 3 million euros. Dies war Teil des geänderten Plans von 2020, der mit 2,745,223 Ja-Stimmen, 376,961 Gegenstimmen und 31,356 Enthaltungen angenommen wurde.

InvestingPro Acknowledgment

The view on the financial interests of Aethlon Medical Inc. (NASDAQ:AEMD) provides InvestingPro together with the financing context for anleger. The active market capitalization of the companies was a modest amount of 6.2 million US dollars, the Small-Cap status was not available.

InvestingPro-Tipps enabled AEMD to make more money in Bilanz’s fisheries, increasing the financial flexibility of the financing phase. Many things about the US market – a critical factor, the investors focus on the young financial company and can adopt more strategic new directions.

The performance of the promotion is volatile: a strong performance of 22.61% in the month represents a return of 75.08% in the Monaten movements. With the InvestingPro tip of the high volatility of the AEMD action in the past and the note of a sorgfältige risk calculation for potential investors, these Schwan-kungen are unpaid.

For part of the analysis, InvestingPro offers 12 other tips, which make some of the financial prosperity and market position of AEMDs a lot more attractive.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.